Table 4.
Human doses (in mSv/MBq) estimates for [18F]Nifene generated with OLINDA 1.1 software using residence times estimated from the mouse residence times.
| Target Organ | Male average (± SD) | Female average (± SD) | |
|---|---|---|---|
| Adrenals | 1.29E-02 ± 1.26E-03 | 1.25E-02 ± 1.15E-03 | |
| Brain | 8.09E-03 ± 9.55E-04 | 8.52E-03 ± 2.86E-04 | |
| Breasts | 8.85E-03 ± 6.47E-04 | 8.63E-03 ± 9.10E-04 | |
| Gallbladder Wall | 1.36E-02 ± 1.10E-03 | 1.25E-02 ± 1.07E-03 | |
| LLI Wall* | 1.52E-02 ± 6.00E-04 | 1.65E-02 ± 1.09E-03 | |
| Small Intestine | 1.41E-02 ± 4.58E-04 | 1.33E-02 ± 7.30E-04 | |
| Stomach Wall | 1.92E-02 ± 3.56E-03 | 1.89E-02 ± 1.38E-03 | |
| ULI Wall* | 1.31E-02 ± 8.02E-04 | 1.30E-02 ± 1.03E-03 | |
| Heart Wall | 1.22E-02 ± 9.17E-04 | 1.17E-02 ± 1.02E-03 | |
| Kidneys | 3.11E-02 ± 1.27E-02 | 2.26E-02 ± 3.03E-03 | |
| Liver | 1.34E-02 ± 2.41E-03 | 1.38E-02 ± 9.75E-04 | |
| Lungs | 9.12E-03 ± 5.14E-04 | 8.46E-03 ± 4.64E-04 | |
| Muscle | 1.09E-02 ± 6.66E-04 | 1.05E-02 ± 8.91E-04 | |
| Ovaries | NA | 1.44E-02 ± 6.65E-04 | |
| Pancreas | 1.69E-02 ± 4.38E-03 | 1.73E-02 ± 2.44E-03 | |
| Red Marrow | 1.01E-02 ± 6.66E-04 | 9.73E-03 ± 8.63E-04 | |
| Osteogenic Cells | 1.76E-02 ± 6.93E-04 | 1.70E-02 ± 3.21E-03 | |
| Skin | 8.43E-03 ± 5.82E-04 | 8.10E-03 ± 7.98E-04 | |
| Spleen | 1.70E-02 ± 3.44E-03 | 1.61E-02 ± 1.82E-03 | |
| Testes | 1.17E-02 ± 3.43E-03 | NA | |
| Thymus | 9.15E-03 ± 7.82E-04 | 9.60E-03 ± 5.97E-04 | |
| Thyroid | 1.10E-02 ± 8.62E-04 | 9.80E-03 ± 1.07E-03 | |
| UB Wall* | 5.74E-02 ± 1.81E-02 | 9.32E-02 ± 2.63E-02 | |
| Uterus | NA | 2.15E-02 ± 3.14E-03 | |
| Total Body | 1.12E-02 ± 7.00E-04 | 1.10E-02 ± 8.85E-04 | |
|
| |||
| Effective dose equivalent | 1.68E-02 ± 2.65E-04 | 1.83E-02 ± 9.74E-04 | |
| Effective dose | 1.51E-02 ± 4.04E-04 | 1.65E-02 ± 8.73E-04 | |
LLI = lower large intestine, ULI = upper large intestine, UB = urinary bladder